MCLEAN, Va. / Jul 16, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the publication of its 2024 Corporate Responsibility Report.
The 2024 report showcases the Company’s strategic momentum in advancing its sustainability priorities during a pivotal year of transformation. The report emphasizes Claritev’s continued focus on managing, tracking and disclosing its social and environmental performance, reinforcing its commitment to accountability and responsible growth.
“I’ve never been more excited about the opportunity ahead—to reshape healthcare through technology, data and insights that drive affordability, transparency and quality across the healthcare ecosystem,” said Travis Dalton, Chairman, and CEO of Claritev.
Dalton continued, “I’m especially proud of our efforts to drive greater access and equity in healthcare. Our partnership with the National Rural Health Association helps extend the reach of our technology and data science capabilities to underserved communities.”
The report outlines Claritev’s progress across key corporate responsibility priorities, including access to healthcare, data privacy and security, people strategy, ethics and transparency, and sustainable operations. Notable 2024 highlights include:
The full report is available on Claritev’s website at the following link: https://www.claritev.com/corporate-responsibility/
About Claritev
Claritev, formerly known as MultiPlan, is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality. Led by a team of deeply experienced associates, data scientists and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose-built solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.
Last Trade: | US$29.20 |
Daily Volume: | 0 |
Market Cap: | US$472.160M |
October 08, 2025 August 06, 2025 July 08, 2025 May 22, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load